Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of Kinnate’s previously announced pursuit of strategic alternatives. This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden... Read More

SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby XOMA Corporation ("XOMA") will acquire Kinnate for a price per share of Kinnate common stock ("Kinnate common stock") of between $2.3352 and $2.5879 in... Read More

Reported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 selective program in the fourth quarter of 2023 Previously announced strategic reprioritization with a focus on exarafenib combination in NRAS... Read More

Promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 selective program in the fourth quarter of 2023 Completed exarafenib monotherapy dose expansion enrollment and cleared efficacious dose for KIN-3248, FGFR... Read More

Received FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023 Cash, cash equivalents and investments of $204.3 million as of June 30, 2023 anticipated to fund operations into early 2025 SAN FRANCISCO and SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate” or the “Company”), a... Read More

SAN FRANCISCO and SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will participate in two upcoming investor conferences: Wednesday, June 7 at 2:30 p.m. ET / 11:30 a.m. PT at the Jefferies Healthcare Conference. Neha Krishnamohan , chief financial officer and executive vice president, corporate... Read More

Presented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting Provided update on ongoing exarafenib monotherapy dose expansion; data-informed strategy prioritizes enrollment in BRAF Class II-driven solid tumors Disclosed early, compelling responses with exarafenib plus binimetinib from the ongoing dose escalation combination arm, primarily in NRAS... Read More

KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023 KIN-8741, a highly selective c-MET inhibitor designed to cover acquired resistance in non-small cell lung cancer and other advanced adult solid tumors, is expected to enter the clinic in the first half of 2024 Kinnate to evaluate strategic alternatives for its CDK12... Read More

Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse events Breadth of responses observed across tumor types and BRAF or NRAS alterations with a total of 8 partial responses in the monotherapy and combination arms Monotherapy dose expansion ongoing at 300 mg bid; data-informed strategy prioritizes enrollment in BRAF Class... Read More

Announced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research 2023 Annual Meeting Announced the company has initiated enrollment of patients into the monotherapy expansion cohorts evaluating exarafenib Announced the U.S. Food and Drug Administration granted Fast Track designation for... Read More

Company has initiated enrollment of patients into the monotherapy expansion cohorts Company to host a virtual investor webcast on April 17, 2023, to discuss the AACR results and dose expansion strategy, and to provide additional pipeline updates SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that... Read More

Kinnate to retain Kinnjiu’s cash, intellectual property and other assets, including key personnel and legal entity structure Kinnate’s cash runway still expected to fund current operations into mid-2024 Trial sites open in People's Republic of China (PRC) and Taiwan for ongoing Phase 1 clinical trial evaluating exarafenib, a pan-RAF inhibitor Kinnate to maintain strategic presence in PRC, Hong Kong, Macau and Taiwan SAN... Read More

SAN FRANCISCO and SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’s investigational pan-FGFR inhibitor, KIN-3248, for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma (CCA)... Read More

SAN FRANCISCO and SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan , will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 1:40 p.m. ET / 10:40 a.m. PT. Members of the Kinnate management team will also host... Read More

SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1, 2023. Ms. DeSimone brings more than forty years of global business expertise in life sciences to Kinnate’s board of directors. Dean J.... Read More

SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822 ) evaluating the Company’s investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology (ASCO)-related... Read More